| Nasdaq: IMGN
ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology. Its ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells. The company's compound with its ADC technology is Roche's Kadcyla. It has four wholly owned clinical-stage product candidates, with additional compounds in the clinic through its partnerships. ImmunoGen was founded in March 1981 and is headquartered in Waltham, MA.